BSEBoard Meeting4d ago · 8 Aug 2026, 02:56 pm

Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....

Norris Medicines Ltd · 524414

✦ AI SummaryResults

Norris Medicines Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/08/2026 to consider and approve Unaudited Financial Results for the quarter ended June 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Norris Medicines Ltd - 524414 - Board Meeting Intimation for Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements, 2015 For Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter Ended June 30, 2026

Attachments (1)

📄

83f1770b-a8cc-44e1-a2c3-3e72eaf7c7cd.pdf

pdf

Download →
View document text
Date: 08th August, 2026 Department of Corporate Service (DCS-CRD), BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001. Script Code: 524414 Sub.: Intimation under regulation 29 of SEBI Listing Obligation and Disclosure Requirements, 2015 for holding Board Meeting for approval of Un-audited financial results for the quarter ended June 30th, 2026 and other matters. Dear Sir, This is to inform you that, the meeting of the Board of Directors of the Company Norris Medicines Limited scheduled to be held on Friday, 14th August, 2026 at the Registered office of the Company situated at Plot No.801/P, GIDC, Ankleshwar, Gujarat, 393002, to transact the following business. 1. To consider and approve Un-audited Financial Results for the quarter ended 30th June, 2026 along with Limited Review Report thereof. 2. Any other business with permission of Chair. Further, as communicated earlier, in accordance with Company’s Code of Conduct for Prevention of Insider Trading in securities of the Company and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in securities of the Company is already closed from July 01, 2026 until Forty-Eight (48) hours after declaration of Un-audited financial results for the quarter ended June 30, 2026 on Stock Exchange. Kindly take the same on your records. Thanking You, Yours truly, FOR NORRIS MEDICINES LIMITED VIMAL SHAH DIRECTOR DIN: 01506655